Changing Epidemiology of Pediatric Pulmonary Exacerbations in Cystic Fibrosis.

ABSTRACT:

Rationale

The introduction of elexacaftor/tezacaftor/ivacaftor (ETI), a highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy, to younger ages and the COVID-19 pandemic have significantly reduced pulmonary exacerbations requiring hospitalization among children with CF.

Objective

To assess demographic and clinical characteristics of children and young adults with CF hospitalized for pulmonary exacerbations before and after pediatric ETI approval.

Methods

A retrospective chart review was conducted at five United States CF Foundation-accredited care centers. Hospitalization data from children and young adults with CF in 2018 and 2022 were analyzed.

Results

Hospitalizations decreased from 471 cases (241 individuals) in 2018 t

SUBMITTER: Fireizen Y 

PROVIDER: S-EPMC12043277 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature